Dr. Marta L. Davila, MD

Dr. Davila practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Davila's NPI, 1770682437, was assigned on September 21, 2006. Dr. Davila graduated from Harvard Medical School in 1988. Dr. Davila holds Texas license M0390.

Dr. Davila's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Davila's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. Dr. Davila is also affiliated with Houston Methodist Hospital. The medical group on file is Physicians Referral Service.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Davila practices, 2 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Davila's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Davila is board certified in gastroenterology by the American Board of Internal Medicine. Dmand AI has Dr. Davila's licenses on file in 3 states: Texas, Florida and California.

Dmand AI lists acid reflux, colonoscopy, gastroenteritis, gastrointestinal bleeding, irritable bowel syndrome (IBS) and upper GI endoscopy among the conditions Dr. Davila treats.

CMS data shows 608 Medicare services from Dr. Davila across 10 procedure codes in 2024, for 379 Medicare patients. Medicare paid $61,087 for them.

CMS counts 379 Medicare patients who saw Dr. Davila in 2024. The largest group is 65 to 74, with 190 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 5% are also on Medicaid. Their average risk score is 1.91, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Davila's median patient age at 72, with 50% women.

In 2024, Dr. Davila wrote 310 Medicare Part D claims for 118 patients. 97% of them were for generic drugs. CMS names the drug for 247 of them, across 7 drugs with 11 or more claims each, at $6,795 in total drug cost. In 2023, CMS named 299 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Davila for performance year 2024, reported as part of a group. Dr. Davila accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Davila as offering telehealth. CMS counts 315 procedures of upper gastrointestinal (gi) endoscopy for acid reflux by Dr. Davila, more than 96% of the clinicians it reports for that procedure.

Dmand AI links 21 papers to Dr. Davila, published from 2006 to 2022. 2012 was the busiest year, with 2. The most frequent topics are Liver Neoplasms, Adenocarcinoma and Hepatitis C. Dr. Davila has published most often in Gastrointest Endosc. Dr. Davila's most frequent co-authors are Harrys Antonio Torres, MD, Manoop S. Bhutani, MD and Raquel Eunice Davila, MD.

CMS Open Payments shows 5 general payments to Dr. Davila from 2 drug and device companies from 2022 to 2024. Food and beverage make up the largest share, 100% of the total. Olympus America Inc. paid the most, $84.

Dr. Davila graduated from Harvard Medical School in 1988.

Dr. Davila is in network with 9 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 6. Check the plan with the practice before a visit.